Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Have previously untreated, pathologically confirmed resectable Stage II, IIIA, or Selected IIIB NSCLC. Staging should be based on the 8th edition of the AJCC/UICC staging system
Evaluation by an attending thoracic surgeon to confirm eligibility for an R0 resection with curative intent
Adequate tumor tissue sample blocks for central programmed death-ligand 1 (PD-L1) testing
Measurable disease as defined by RECIST v1.1
Adequate organ function
Women of childbearing age without sterilizing or male, must agree to use contraception or practice abstinence at least 180 days after the last dose of study treatment
You may not be if
Any previous systematic anti-cancer therapy for lung cancer
With active, known or suspected autoimmune disease of autoimmune disease
Malignancies other than NSCLC within 5 years prior to randomization
Has or suspected has a history of pneumonitis /interstitial lung disease or any serve lung diseases which will influence the examination of lung function
Significant history of cardiovascular and cerebrovascular disease
Significant haemorrhagic disease
Has an arteriovenous thrombotic events
Has a known history of human immunodeficiency virus (HIV) infection
Has a known active Hepatitis B or Hepatitis C
Allergic to monoclonal antibodies or other protein drugs
Allergic to the intervention regimens
Pregnant or lactating women
Has known psychiatric or substance abuse disorders
Confirmed COVID-19 infection or suspected COVID-19 infection or close contact with a person with known or suspected COVID-19 infection.
Clareo Health | A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC
